Skip to main content

Aurinia Pharmaceuticals to Release First Quarter 2022 Financial and Operational Results on May 10, 2022

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) today announced that it will release financial and operational results for first quarter 2022 on Tuesday, May 10, 2022, before markets open. Aurinia’s management team will host a conference call/webcast at 8:30 am ET that day to review these results and provide a general business update.

Interested participants can dial +1-877-407-9170 (Toll-free U.S. & Canada). The audio webcast can also be accessed under "News/Events” through the “Investors” section of the Aurinia corporate website at www.auriniapharma.com. A replay of the webcast will be available on Aurinia’s website.

About Aurinia

Aurinia is a fully integrated biopharmaceutical company focused on delivering therapies to treat targeted patient populations that are impacted by serious diseases with a high unmet medical need. In January 2021, the Company introduced the first FDA-approved oral therapy indicated for the treatment of adult patients with active lupus nephritis (LN). Aurinia’s head office is in Victoria, British Columbia; its U.S. commercial hub is in Rockville, Maryland; and the Company focuses development efforts globally.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.71
-3.32 (-1.50%)
AAPL  260.29
-2.48 (-0.95%)
AMD  239.76
+1.73 (0.73%)
BAC  51.08
-0.44 (-0.85%)
GOOG  255.52
+4.18 (1.66%)
META  738.62
+5.35 (0.73%)
MSFT  523.66
+6.00 (1.16%)
NVDA  183.06
+1.90 (1.05%)
ORCL  275.86
+0.71 (0.26%)
TSLA  441.68
-0.92 (-0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.